Post-Marketing Observational Study of Safety Following Vaccination With Flublok Compared to Licensed IIV in Adults 18 Years of Age and Older

Trial Profile

Post-Marketing Observational Study of Safety Following Vaccination With Flublok Compared to Licensed IIV in Adults 18 Years of Age and Older

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Protein Sciences Corporation
  • Most Recent Events

    • 11 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 17 Jun 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 17 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top